Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.49 |
| ▸ | PDE4A | P27815 | 7/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.44 |
| ▸ | F2 | P00734 | 6/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903646 | 0.87 | F10 (0.50) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6900491 | 0.86 | F10 (0.66) | F10F2 | |
| SCHEMBL6900785 | 0.81 | F10 (0.48) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3872417 | 0.78 | CCNA2 (0.52) | F10F2SLC29A1 | |
| SCHEMBL3875555 | 0.75 | F10 (0.59) | F10F2SLC29A1 | |
| SCHEMBL2003340 | 0.75 | F10 (0.53) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1997349 | 0.72 | F10 (0.68) | F10F2 | |
| SCHEMBL5306322 | 0.71 | ALDH1A1 (0.54) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5251278 | 0.70 | F10 (0.72) | F10F2 | |
| SCHEMBL8359222 | 0.69 | F10 (0.68) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750225-B2 | ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMS COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-6706730-B2 | ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030022916-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-30 | — | — | US | disclosed |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | SERPINC1, SERPINE1, F11 | F10 31/4885PDE4A 2491/4885PDE4B 2144/4885 |
| US-20030022916-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor Xa inhibitors | SERPINC1, SERPINE1, F11 | F10 34/4885PDE4A 1842/4885PDE4B 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.